```html

Renal Cell Carcinoma (RCC) – Comprehensive Medical Guide

Overview

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, arising from the renal tubular epithelium. It accounts for about 85‑90% of all malignant kidney tumors and roughly 2–3% of all adult cancers worldwide.

Who it affects: RCC can develop at any age, but the median age at diagnosis is 64 years. Men are about 1.5‑2 times more likely to develop RCC than women. Incidence is higher in people of European ancestry and lower in Asian and African populations.

Prevalence: In the United States, the American Cancer Society estimates 79,000 new cases and 13,900 deaths from kidney cancer (including RCC) in 2024. The incidence has risen modestly over the past two decades, largely due to improved imaging that detects asymptomatic tumors.

Symptoms

Many early RCCs are silent and discovered incidentally on imaging for unrelated reasons. When symptoms appear, they can be vague. The classic triad—flank pain, hematuria, and a palpable abdominal mass—is now seen in < 10% of cases, but the following list covers the full spectrum of possible manifestations.

• Blood in the urine (hematuria) – bright red or pink urine, sometimes painless.
• Flank or back pain – dull, persistent pain on the side of the affected kidney; may radiate to the lower abdomen.
• Palpable mass – a firm lump in the abdomen or side, often only detectable when the tumor is large.
• Unexplained weight loss – loss of 5% or more of body weight without dieting.
• Fever – low‑grade or intermittent, not linked to infection.
• Fatigue – persistent tiredness, often due to anemia.
• Night sweats – excessive sweating during sleep.
• Paraneoplastic syndromes (symptoms caused by substances the tumor releases):
  • High blood pressure (renin excess)
  • Erythrocytosis (excess red blood cells due to erythropoietin)
  • Hypercalcemia (calcium elevation from parathyroid‑like hormone)
  • Pediculosis (itchy skin rash)
• Painful urination or urinary urgency – less common, may occur if the tumor invades the collecting system.
• Bone pain or fractures – indicates metastatic disease to bone.

Because many of these signs overlap with less serious conditions, any unexplained hematuria or persistent flank pain should prompt medical evaluation.

Causes and Risk Factors

The exact cause of RCC is not fully understood, but several genetic and environmental factors increase risk.

Genetic and hereditary factors

• Von Hippel‑Lindau (VHL) disease – a mutation in the VHL tumor‑suppressor gene; patients have a 30‑50% lifetime risk of RCC.
• Hereditary papillary renal carcinoma (MET gene mutation).
• Birt‑Hogg‑Dubé syndrome (FLCN gene mutation).
• Familial renal cell carcinoma – rare, autosomal‑dominant inheritance.

Acquired risk factors

• Smoking – current smokers have a 1.5‑2‑fold increased risk; risk declines after cessation but remains elevated for 10‑20 years.
• Obesity – each 5‑kg/m² increase in BMI raises RCC risk by about 20% (NIH, 2023).
• Hypertension – long‑standing high blood pressure is associated with a 30‑40% higher risk.
• Chronic kidney disease (CKD) & dialysis – especially in patients on long‑term hemodialysis.
• Occupational exposures – exposure to asbestos, cadmium, trichloroethylene, or petroleum products.
• Family history of kidney cancer – first‑degree relative doubles the risk.

Diagnosis

RCC diagnosis proceeds from suspicion (based on signs or incidental imaging) to confirmation with imaging, laboratory studies, and pathologic evaluation.

Imaging studies

• Ultrasound – often the first test for hematuria; can detect solid masses.
• Contrast‑enhanced CT scan (abdomen & pelvis) – gold standard for tumor size, location, and local invasion; provides “enhancement” pattern typical of RCC.
• Magnetic Resonance Imaging (MRI) – used when CT contrast is contraindicated (e.g., poor kidney function) and for assessing venous involvement.
• Chest CT – screens for lung metastases, the most common site of spread.
• Bone scan or PET/CT – indicated when bone pain or elevated alkaline phosphatase suggests skeletal metastases.

Laboratory tests

• Complete blood count (CBC) – anemia may be present.
• Serum chemistry – calcium, liver function, and renal function panels.
• Urine analysis – confirms hematuria, rules out infection.
• Serum erythropoietin – may be elevated in paraneoplastic erythrocytosis.

Pathology

The definitive diagnosis requires a tissue sample.

• Core needle biopsy – image‑guided, increasingly used when systemic therapy is being considered.
• Surgical excision specimen – provides the most comprehensive histologic evaluation.

Pathologists grade RCC using the WHO/ISUP grading system (grades 1‑4) and classify histologic subtypes (clear cell, papillary, chromophobe, collecting‑duct, etc.), which guide treatment decisions.

Treatment Options

Treatment is individualized based on tumor stage, histology, patient comorbidities, and personal preferences. Options include surgery, ablative therapies, systemic medications, and supportive care.

Surgical approaches

• Partial nephrectomy (nephron‑sparing surgery) – preferred for tumors ≤7 cm (cT1) when feasible; preserves renal function.
• Radical nephrectomy – removal of the entire kidney, perirenal fat, and sometimes adrenal gland; standard for larger or centrally located tumors.
• Laparoscopic or robot‑assisted techniques – provide similar oncologic outcomes with shorter hospital stay and less pain.

Ablative therapies (for small tumors or poor surgical candidates)

• Radiofrequency ablation (RFA)
• Cryoablation
• High‑intensity focused ultrasound (HIFU) – investigational.

Systemic therapies

Used for metastatic disease or when surgery is not curative.

• Targeted therapy – VEGF pathway inhibitors (e.g., sunitinib, pazopanib, axitinib) and mTOR inhibitors (everolimus, temsirolimus).
• Immunotherapy – checkpoint inhibitors such as nivolumab (PD‑1), pembrolizumab, and combination regimens (e.g., ipilimumab + nivolumab). These have become first‑line for many patients with advanced RCC.
• Combination regimens – VEGF‑TKI plus immunotherapy (e.g., pembrolizumab + axitinib) improve overall survival in recent phase III trials (KEYNOTE‑426).
• Adjuvant therapy – after nephrectomy for high‑risk patients, pembrolizumab is FDA‑approved (2023) to reduce recurrence.

Radiation therapy

Historically radio‑resistant, but stereotactic body radiotherapy (SBRT) is useful for palliation of bone or brain metastases and for local control when surgery isn’t possible.

Lifestyle and supportive measures

• Smoking cessation – improves response to systemic therapy.
• Weight management – may reduce recurrence risk.
• Blood pressure control – essential for overall cardiovascular health.
• Nutrition counseling – adequate protein intake post‑surgery; avoid high‑sodium diets if hypertension is present.

Living with Renal Cell Carcinoma

Life after diagnosis involves ongoing surveillance, managing side effects, and maintaining overall wellness.

Surveillance schedule

• First 2 years after curative surgery: CT or MRI every 6 months.
• Years 3‑5: imaging annually.
• Lifelong annual physical exam and labs (CBC, renal function, calcium).

Follow‑up intervals may be intensified if high‑grade pathology or positive lymph nodes were present.

Managing treatment side effects

• Targeted therapy – hand‑foot skin reaction, hypertension, diarrhea, fatigue; monitor blood pressure and treat skin changes with moisturizers, dose adjustments.
• Immunotherapy – immune‑related adverse events (colitis, hepatitis, pneumonitis); early recognition and corticosteroid therapy are crucial.
• Post‑operative care – pain control, early ambulation, deep‑breathing exercises to prevent atelectasis.

Emotional and psychosocial support

Joining a kidney‑cancer support group, engaging with a mental‑health professional, and using patient portals for quick communication with the oncology team can reduce anxiety and improve adherence.

Practical daily tips

• Stay hydrated – aim for 2–3 L of water daily unless fluid restriction is ordered.
• Monitor urine color and volume; report new blood or pain promptly.
• Maintain a balanced diet rich in fruits, vegetables, whole grains, and lean protein.
• Keep a medication log, especially when on oral TKIs or immunotherapies.
• Schedule regular physical activity (e.g., 30 min brisk walking most days) as tolerated.

Prevention

While RCC cannot be completely prevented, modifiable risk factors can be addressed.

• Never start smoking; quit if you smoke. Resources: CDC quit line.
• Maintain a healthy weight. Aim for BMI < 25 kg/m²; incorporate regular exercise.
• Control blood pressure. Follow DASH diet, limit sodium, and take antihypertensives as prescribed.
• Limit occupational exposures. Use protective equipment when handling solvents or heavy metals.
• Regular health check‑ups. For individuals with a family history or genetic syndrome, discuss screening (e.g., periodic abdominal imaging) with a nephrologist or oncologist.

Complications

If RCC is left untreated or not adequately controlled, several serious complications can arise.

• Local invasion – tumor can infiltrate renal vein, inferior vena cava, or surrounding organs, causing pain, hematuria, or pulmonary embolism.
• Metastatic spread – lungs (most common), bones, liver, brain; leads to organ‑specific symptoms and reduced survival.
• Paraneoplastic syndromes – severe hypertension, hypercalcemia, or erythrocytosis that may cause cardiovascular events or thromboembolic disease.
• Renal insufficiency – loss of kidney function after radical nephrectomy, especially in patients with pre‑existing CKD.
• Post‑surgical complications – infection, bleeding, pulmonary embolism, or wound dehiscence.
• Treatment‑related toxicities – chronic fatigue, cardiomyopathy (rare with some TKIs), or autoimmune organ damage from immunotherapy.

When to Seek Emergency Care

For non‑emergent concerns, schedule a prompt appointment with your urologist, oncologist, or primary‑care provider.

---

Sources: Mayo Clinic, CDC, National Cancer Institute, American Cancer Society, Cleveland Clinic, World Health Organization, peer‑reviewed journals (JCO 2023; NEJM 2022). All links accessed April 2026.

```